Known targets — ChEMBL curated mechanism
ADRB1ADRB2ATP4AATP4BAXLCHRM2CHRM3DRD2FLT3HRH1HTR2AHTR2BHTR2CKCNH2KMT2AMAP2K1MAP2K2MEN1MLNRPLK4RENS1PR1SLC6A2SLC6A4atpAatpBatpCatpDatpEatpFatpFHatpGpol
The experimentally established mechanism targets of Propionyl-Carnitine. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MEN1 known ✓ | O00255 | 5/20 | 0.82 |
| ▸ | KMT2A known ✓ | Q03164 | 5/20 | 0.82 |
| ▸ | HRH1 known ✓ | P35367 | 1/20 | 0.58 |
| ▸ | CYP2C19 | P33261 | 2/20 | 0.82 |
| ▸ | RECQL | P46063 | 1/20 | 0.82 |
| ▸ | MAPT | P10636 | 4/20 | 0.58 |
| ▸ | SLC25A20 | O43772 | 3/20 | 0.58 |
| ▸ | TP53 | P04637 | 3/20 | 0.58 |
| ▸ | TSHR | P16473 | 3/20 | 0.58 |
| ▸ | CYP2D6 | P10635 | 2/20 | 0.58 |
| ▸ | SLC6A5 | Q9Y345 | 2/20 | 0.58 |
| ▸ | CYP2C9 | P11712 | 2/20 | 0.58 |
| ▸ | HIF1A | Q16665 | 2/20 | 0.58 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.58 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.58 |
| ▸ | NFKB1 | P19838 | 1/20 | 0.58 |
| ▸ | THPO | P40225 | 1/20 | 0.58 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.58 |
| ▸ | CYP1A2 | P05177 | 4/20 | 0.58 |
| ▸ | MAPK1 | P28482 | 4/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Propionyl-Carnitine SCHEMBL7942755 | 1.00 | MEN1 (0.82) | MEN1KMT2ACYP2C19RECQLMAPT | |
| Levocarnitine Propionate SCHEMBL2232689 | 1.00 | MEN1 (0.82) | MEN1KMT2ACYP2C19RECQLMAPT | |
| Propionyl-Carnitine SCHEMBL156850 | 0.91 | MEN1 (1.00) | MEN1KMT2ACYP2C19RECQLMAPT | |
| Levocarnitine Propionate SCHEMBL464940 | 0.91 | MEN1 (1.00) | MEN1KMT2ACYP2C19RECQLMAPT | |
| Propionyl-Carnitine SCHEMBL994714 | 0.91 | MEN1 (1.00) | MEN1KMT2ACYP2C19RECQLMAPT | |
| Propionyl-Carnitine SCHEMBL19617435 | 0.89 | MEN1 (0.90) | MEN1KMT2ACYP2C19RECQLMAPT | |
| Levocarnitine Propionate SCHEMBL3005249 | 0.89 | MEN1 (0.97) | MEN1KMT2ACYP2C19RECQLMAPT | |
| Levocarnitine Propionate SCHEMBL1358528 | 0.89 | MEN1 (0.97) | MEN1KMT2ACYP2C19RECQLMAPT | |
| Propionyl-Carnitine SCHEMBL1358526 | 0.89 | MEN1 (0.97) | MEN1KMT2ACYP2C19RECQLMAPT | |
| Propionyl-Carnitine SCHEMBL7561314 | 0.88 | MEN1 (0.82) | MEN1KMT2ACYP2C19RECQLMAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 35 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230346735-A1 | Nutritional Composition Comprising Carnitine and Method for Treating or Preventing an Infection in a Mammal | LONZA GREENWOOD LLC | 2023-11-02 | — | — | US | claimed |
| EP-4125858-A1 | NUTRITIONAL COMPOSITION COMPRISING CARNITINE AND METHOD FOR TREATING OR PREVENTING AN INFECTION IN A MAMMAL | Lonza Consumer Health Inc. (US) | 2023-02-08 | — | — | EP | claimed |
| WO-2021221741-A1 | NUTRITIONAL COMPOSITION COMPRISING CARNITINE AND METHOD FOR TREATING OR PREVENTING AN INFECTION IN A MAMMAL | LONZA CONSUMER HEALTH INC. (US) | 2021-11-04 | — | — | WO | claimed |
| US-6217898-B1 | ANTICHOLESTEROL AGENTS | SIGMA-TAU HEALTHSCIENCE S.P.A. (IT) | 2001-04-17 | — | — | US | claimed |
| US-4602039-A | HYDROPHOPIC;BIOLOGICAL INJECTIONS | SIGMA-TAU INDUSTRIE FARMACEUTICHE RIUNITE S.P.A. (IT) | 1986-07-22 | — | — | US | claimed |
| EP-4125858-B1 | NUTRITIONAL COMPOSITION COMPRISING L-CARNITINE TARTRATE FOR USE IN TREATING OR PREVENTING A CORONAVIRUS INFECTION IN A MAMMAL | LONZA GREENWOOD LLC (US) | 2026-05-06 | — | — | EP | disclosed |
| US-20230346735-A1 | Nutritional Composition Comprising Carnitine and Method for Treating or Preventing an Infection in a Mammal | LONZA GREENWOOD LLC | 2023-11-02 | — | — | US | disclosed |
| EP-3154539-B1 | METHOD FOR DECREASING SKELETAL MUSCLE DAMAGE AND/OR OXIDATIVE STRESS IN MAMMALS | LONZA CONSUMER HEALTH INC (US) | 2023-03-22 | — | — | EP | disclosed |
| EP-4125858-A1 | NUTRITIONAL COMPOSITION COMPRISING CARNITINE AND METHOD FOR TREATING OR PREVENTING AN INFECTION IN A MAMMAL | Lonza Consumer Health Inc. (US) | 2023-02-08 | — | — | EP | disclosed |
| US-20220370393-A1 | METHOD AND COMPOSITION FOR INCREASING MUSCLE PROTEIN SYNTHESIS | CAPSUGEL BELGIUM NV (BE) | 2022-11-24 | — | — | US | disclosed |
| US-20220370392-A1 | Method and Composition for Increasing Muscle Protein Synthesis | CAPSUGEL BELGIUM NV (BE) | 2022-11-24 | — | — | US | disclosed |
| EP-4027991-A1 | METHOD AND COMPOSITION FOR INCREASING MUSCLE PROTEIN SYNTHESIS | Capsugel Belgium NV (BE) | 2022-07-20 | — | — | EP | disclosed |
| WO-2015191827-A1 | METHOD FOR DECREASING SKELETAL MUSCLE DAMAGE AND/OR OXIDATIVE STRESS IN MAMMALS | LONZA INC. (US) | 2015-12-17 | — | — | WO | disclosed |
| EP-2531189-B1 | Combination composition, comprising as active ingredient l-carnitine or propionyl l-carnitine, for the prevention or treatment of chronic venous insufficiency | SIGMA TAU IND FARMACEUTI (IT) | 2014-06-11 | — | — | EP | disclosed |
| US-20140018310-A1 | COMBINATION COMPOSITION, COMPRISING AS ACTIVE INGREDIENTS L-CARNITlNE OR PROPIONYL L-CARNITlNE, FOR THE PREVENTION OR TREATMENT OF CHRONIC VENOUS INSUFFICIENCY | SIGMA-TAU INDUSTRIE FARMACEUTICHE RIUNITE S.P.A. (IT) | 2014-01-16 | — | — | US | disclosed |
| US-20130005670-A1 | COMBINATION COMPOSITION, COMPRISING AS ACTIVE INGREDIENTS L-CARNITlNE OR PROPIONYL L-CARNITlNE, FOR THE PREVENTION OR TREATMENT OF CHRONIC VENOUS INSUFFICIENCY | SIGMA-TAU INDUSTRIE FARMACEUTICHE RIUNITE S.P.A. (IT) | 2013-01-03 | — | — | US | disclosed |
| EP-2531189-A1 | COMBINATION COMPOSITION, COMPRISING AS ACTIVE INGREDIENT L-CARNITINE OR PROPIONYL L-CARNITINE, FOR THE PREVENTION OR TREATMENT OF CHRONIC VENOUS INSUFFICIENCY | Sigma-Tau Industrie Farmaceutiche Riunite S.P.A. (IT) | 2012-12-12 | — | — | EP | disclosed |
| WO-2011095882-A1 | COMBINATION COMPOSITION, COMPRISING AS ACTIVE INGREDIENT L-CARNITINE OR PROPIONYL L-CARNITINE, FOR THE PREVENTION OR TREATMENT OF CHRONIC VENOUS INSUFFICIENCY | SIGMA-TAU INDUSTRIE FARMACEUTICHE (IT) | 2011-08-11 | — | — | WO | disclosed |
| EP-2353596-A1 | Combination composition, comprising as active ingredients L-carnitine or propionyl L-carnitine, for the prevention or treatment of chronic venous insufficiency | SIGMA-TAU Industrie Farmaceutiche Riunite S.p.A. (IT) | 2011-08-10 | — | — | EP | disclosed |
| US-20110189152-A1 | Combination composition, comprising as active ingredients L-carnitine or propionyl L-carnitine, for the prevention or treatment of chronic venous insufficiency | SIGMA-TAU INDUSTRIE FARMACEUTICHE RIUNITE S.P.A. (IT) | 2011-08-04 | — | — | US | disclosed |